Neurizon Therapeutics Limited

NUZ

AU0000357261

Pharmaceuticals

Delayed Australian S.E. Other stock markets 07:13:47 08/07/2025 am IST			5-day change	1st Jan Change
0.1600 ^AUD	+3.23%		+3.23%	-5.88%

03/07	Elanco Animal Health Enters Into Licensing Agreement With Neurizon for Monepantel	MT
02/07	Neurizon Therapeutics Secures License Deal With Animal Health Company; Shares Up 3%	MT

Neurizon Therapeutics Limited(ASX:NUZ) dropped from S&P/ASX Emerging Companies Index

Published on 24/03/2025 at 04:30

Latest news about Neurizon Therapeutics Limited

Elanco Animal Health Enters Into Licensing Agreement With Neurizon for Monepantel	03/07	MT
Neurizon Therapeutics Secures License Deal With Animal Health Company; Shares Up 3%	02/07	MT
Neurizon Therapeutics Develops Oral Liquid Formulation for Amyotrophic Lateral Sclerosis Drug Candidate	26/06	MT
Neurizon Therapeutics Says High Levels of NUZ-001 Drug Candidate Cross Blood-Brain Barrier in Rodent Study	20/06	MT
NUZ-001 Shows Promise In Zebrafish Model Of Huntington's Disease	16/06	RE
Neurizon® Therapeutics Limited Announces New Preclinical Data Demonstrating Significant Neuroprotective Effects of Nuz-001 Sulfone	16/06	CI
Neurizon Therapeutics Limited Announces Change of Registered Office and Principal Place of Business Address	02/06	CI
Neurizon Reports No Adverse Events as Final Patient Completes Sclerosis Drug Trial; Shares Fall 4%	05/05	MT
Neurizon Therapeutics Appoints Don O'Connell as Chief Financial Officer; Shares Down 4%	22/04	MT
Neurizon Therapeutics Appoints Dan O'Connell As CFO	22/04	RE
Neurizon Therapeutics Limited Appoints Dan O'Connell as Chief Financial Officer	22/04	CI
Neurizon Therapeutics Makes Three Executive Appointments; Shares Up 15%	17/04	MT
Neurizon Therapeutics Completes Study of Drug Candidate on Mouse Motor Neuron Cell Line	04/04	MT
Neurizon Therapeutics Limited Announces Results from an Additional Independent Study Carried Out in Partnership with the University of Queensland	04/04	CI
Neurizon Therapeutics Limited Announces Results from an Independent Study Conducted in Collaboration with Tessara Therapeutics	01/04	CI
ASX Biggest Gainers	28/03	MT
Neurizon Therapeutics Limited(ASX:NUZ) dropped from S&P/ASX Emerging Companies Index	24/03	CI
Neurizon Therapeutics Limited Provides Update on Preparation for Entry into the Healey & AMG Center	24/03	CI
Neurizon Therapeutics Moves to Lift FDA Suspension on NUZ-001 Drug Candidate with Two Studies; Shares Fall 5%	17/03	MT
Neurizon Therapeutics Logs HY Loss Attributable A$7.3 Mln	17/02	RE
Neurizon Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2024	17/02	CI
Neurizon Therapeutics Says Got Guidance From FDA Placing IND Application For NUZ-001 Under Clinical Hold	17/02	RE
Neurizon Gets US Patent for Cancer Drug Candidate; Shares Up 16%	05/02	MT
Neurizon Therapeutics Says US Patent Granted For NUZ-001	05/02	RE
Neurizon Therapeutics Says FDA Places its Investigational New Drug Application on Hold; Shares Hit New 52-Week Low	17/01	MT

Chart Neurizon Therapeutics Limited

Duration

Period

NUZ: Dynamic Chart

Neurizon Therapeutics Ltd, formerly PharmAust Limited, is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. The Company is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.

Employees

Sector

Pharmaceuticals

Calendar

29/08 - Q4 2025 Earnings Release (Projected)

More about the company